A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

Purpose: To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in patients with advanced solid malignancies. Experimental Design: OSI-7836 was initially given as a 60-minute i.v. infusion on day 1 every 21 days. In view of its dose-limiting to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2006-05, Vol.12 (9), p.2841-2848
Hauptverfasser:	LEE, Chooi P, DE JONGE, Maja J. A, KAYE, Stan B, JUDSON, Ian R, VERWEIJ, Jaap, O'DONNELL, Anne E, SCHOTHORST, Kristel L, HANWELL, Janet, CHICK, Jon B, BROOIMANS, Rik A, ADAMS, Laurel M, DROLET, Daniel W, DE BONO, Johann S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - toxicity Antineoplastic agents Arabinonucleosides - administration & dosage Arabinonucleosides - pharmacokinetics Arabinonucleosides - toxicity Biological and medical sciences chemotherapy Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Male Medical sciences Metabolic Clearance Rate Middle Aged Neoplasms - blood Neoplasms - drug therapy nucleoside analogue pharmacokinetics Pharmacology. Drug treatments Phase I study
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!